Q
We offer choice, value, and convenience for patients while being a sales channel for the licensed producers. It is also a centralized, secure platform where patients do not have to repeatedly switch prescriptions, thus saving time, saving healthcare dollars, preventing abuse, and ensuring patients never run out of their necessary medicine in a shortage. In the US for the hemp-derived CBD market, we provide a physician-led, curated marketplace they can trust while being an additional sales channel to producers that captures customers they otherwise would not see.
A
CannaInvestor Magazine: Canada is a very small market. Is the Canadian market large enough to support your platform?
Cannalogue: Canada is indeed a small market, but it’s a great market to test the model and prove the concept because of the advancements of the Canadian legislation. We’re continuing to grow in Canada, but we also know that our existing technology infrastructure is portable and scalable internationally. We’re expanding imminently to the US hemp-derived CBD market with plans to expand to the UK, EU, and other international jurisdictions.
Q
CannaInvestor Magazine: What legal and compliance challenges did you confront when you launched the Cannalogue platform? What are your future challenges?
A
Cannalogue: When the idea of Cannalogue was first conceived in 2016, the Canadian framework for cannabis was set up mainly for a cultivator. We wrote our application in 2017, went back and forth with Health Canada in 2018, and eventually became licensed in March of 2019.